GEM-DIMER
Live / Allowed — Notice of allowance issued (as of 04 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 12 Dec 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99545865
- Mark type
- Stylized text
- Filed
- 12 Dec 2025
- Published for opposition
- 09 Jun 2026
- Attorney of record
- Beth M. Goldman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations comprising of monospecific, bispecific, or multi-specific antibody based molecules for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions; pharmaceutical agents comprising of monospecific, bispecific, or multi-specific antibody based molecules for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions; monospecific, bispecific, or multi-specific antibody based molecules as a component in pharmaceutical preparations for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions
Owner
- Hinge Bio, Inc., Redwood City, CA, US
- Hinge Bio, Inc., Redwood City, CA, US
Prior registrations
Prosecution history
- 04 Aug 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 09 Jun 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jun 2026 — PUBLISHED FOR OPPOSITION
- 03 Jun 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 May 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Apr 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 29 Apr 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Apr 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 16 Apr 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 16 Apr 2026 — NON-FINAL ACTION E-MAILED
- 16 Apr 2026 — NON-FINAL ACTION WRITTEN
- 16 Apr 2026 — ASSIGNED TO EXAMINER
- 10 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 10 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 10 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED